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The case
A nine year old boy, born of third degree consanguinity, presented with a hard left scapular 
swelling for 6 months. There was no history of fever, trauma or weight loss. There was no 
pain, redness or discharge. This mass was excised but recurred over the next 6 months (Left 
panel of Figure 1). A similar swelling had been excised from the left knee one year before 
presentation, but had recurred over 6 months. Family history was negative for similar 
lesions. Development was normal for age and he had no other medical problems.
On examination, pulse was 84 per minute, blood pressure 96/68 mmHg, weight 22 kg and 
height 122 cm (both between 10th and 25th percentile). A 6 × 4 cm mass was noted in the 
right scapular region and a 3 × 3 cm mass at the lateral aspect of the left knee. Both of these 
masses were firm to hard, globular, nontender, and fixed to the bone. The overlying skin was 
without erythema or local warmth, though scars from the previous resections were noted. 
Lymphadenopathy was absent. The rest of the examination was unremarkable.
Radiographs of the knee showed a lobular, inhomogenously but densely calcified lesion in 
the anterolateral region of the left knee (Right panel of Figure 1). Serum calcium was 9.3 
mg/dl (2.32 mmol/l), phosphate 8.9 mg/dl (2.87 mmol/l, normal range 3.7-5.6 mg/dl), 
creatinine 0.7 mg/dl (61.88 μmol/l), alkaline phosphatase 133 units/L, intact parathyroid 
hormone 5.8 ng/l (16-67 ng/l), 25-hydroxyvitamin D 20.9 ng/ml (>20 ng/ml- sufficiency), 
1,25-dihydroxyvitamin D 30.9 pg/ml (19.6-54.3 pg/ml). Tubular maximum reabsorption of 
phosphate corrected for GFR (TMP/GFR) was 8.5 mg/dl (2.74mmol/l, normal range 3.8-5 
mg/dl).
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What is the diagnosis? What is the treatment?
The Diagnosis: Familial hyperphosphatemic tumoral calcinosis
Familial hyperphosphatemic tumoral calcinosis (FHTC) is a rare autosomal recessive 
disorder of phosphate metabolism characterized by hyperphosphatemia and deposition of 
calcium phosphate in the soft tissues.1
Fibroblast growth factor 23 (FGF23) inhibits sodium-phosphate cotransport in the proximal 
tubule leading to phosphaturia, and inhibits production of 1,25-dihydroxyvitamin D.2 
Decreased activity of FGF23 occurs due to recessive loss-of-function mutations in the 
FGF23 gene or GALNT3 gene (an enzyme that glycosylates FGF23) or due to mutation in 
KLOTHO which encodes a cofactor necessary for FGF23 binding to its receptor.1 InFGF23 
or GALNT3 mutations , the ability to secrete intact biologically active FGF23 is impaired, 
due to increased proteolytic cleavage into inactive fragments. With KLOTHO mutations, 
end-organ response to FGF23 is impaired, causing an FGF23-resistant state. In either 
situations the diminished FGF23 activity leads to increased renal phosphate reabsorption 
indicated by increased TMP/GFR, and sometimes elevated 1,25-dihydroxyvitamin D. 
Progressive soft tissue calcium-phosphate deposition occurs near joints and sometimes in the 
vessel walls..
Radiography identifies a calcified, often lobular lesion. Hyperphosphatemia with normal 
renal function, normal or high serum calcium and 1, 25-dihydroxyvitamin D, and normal or 
suppressed parathyroid hormone are clues to the diagnosis. In the setting of either FGF23 or 
GALNT3 mutations, C-terminal FGF23 levels (measuring fragments plus intact FGF23) are 
elevated consistent with physiologic response to hyperphosphatemia. However, intact 
FGF23 concentrations are low.. However, in the setting of KLOTHO mutation, as an FGF23 
resistant state, both C-terminal and intact FGF23 concentrations were elevated in the only 
case reported to date.4
After surgical resection lesions frequently recur, since the underlying phosphate metabolism 
defect persists. Lesions may enlarge over time and vascular calcifications may occur as well. 
Aggressive management with dietary phosphate restriction and phosphate binders may be of 
benefit, though evidence is limited to case reports.1, 3 Acetazolamide induces phosphaturia 
and has been used with success. 5
Genetic analysis of this patient revealed a previously described homozygous mutation in 
exon 3 of FGF23 causing an amino acid change: S129P. 6 C-terminal FGF23 concentration 
was 1050 RU/ml (normal < 180 RU/ml) and intact FGF23 concentration was 22 pg/ml 
(normal <70 pg/ml), but a “low normal” concentration is an inappropriate physiologic 
response to hyperphosphatemia 2, consistent with the expected pattern due to FGF23 
mutations causing FHTC. After six months of treatment with sevelamer carbonate and 
aluminium hydroxide, the patient's serum phosphate levels have decreased to 6 mg/dl, and 
the lesions have resolved.
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Figure 1. 
Panel on left: The mass in the scapular region had recurred after surgical excision. Panel on 
right: Radiograph showing a recurrent calcified lesion lateral to left knee
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